McNeil labeling deferrals
This article was originally published in The Tan Sheet
Executive Summary
Firm receives six-month deferral from OTC labeling compliance date for 10-count vials of two Tylenol SKUs and two-count pouches of Motrin IB, Tylenol and Imodium products. In Dec. 21 letter, FDA says product labeling must comply with "Drug Facts" requirements by Nov. 16. J&J division originally sought eight-month deferral for vials to allow time for new wrap-around labeling. In November, McNeil requested additional six months to implement "booklet style" labeling on five pouch products (1"The Tan Sheet" Dec. 10, 2001, p. 3)...
You may also be interested in...
McNeil “Drug Facts” Booklet Pouch Labeling Proposed For Two-Count Sizes
McNeil Consumer Healthcare is requesting a six-month deferral from the OTC labeling final rule requirements to implement "booklet pouch" labeling for two-count sizes of five products
Finding The Sweet Spot For Real-World Evidence: Aetion Stresses Early Feasibility Assessment
Robust natural history data sets with well-chosen outcomes are fundamental in Aetion’s regulatory feasibility tool for real-world evidence, built through analysis of US FDA case studies and guidance.
FDA Gene Therapy Office Chief Prefers Flexibility With Accelerated Approval Confirmatory Trials
Ideally, the studies would be underway at the time of approval, as the US FDA’s new authority allows, but Office of Therapeutic Products Director Nicole Verdun sys there will be exceptions.